Goldman Sachs’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.36M | Buy |
1,613,650
+45,229
| +3% | +$300K | ﹤0.01% | 3128 |
|
|
2025
Q4 | $12.3M | Sell |
1,568,421
-227,034
| -13% | -$1.79M | ﹤0.01% | 2887 |
|
|
2025
Q3 | $14.6M | Sell |
1,795,455
-476,031
| -21% | -$3.16M | ﹤0.01% | 2582 |
|
|
2025
Q2 | $10.6M | Sell |
2,271,486
-518,528
| -19% | -$2.38M | ﹤0.01% | 2705 |
|
|
2025
Q1 | $15.3M | Buy |
2,790,014
+1,199,435
| +75% | +$4.84M | ﹤0.01% | 2285 |
|
|
2024
Q4 | $5.39M | Buy |
1,590,579
+754,137
| +90% | +$2.43M | ﹤0.01% | 3379 |
|
|
2024
Q3 | $2.38M | Buy |
836,442
+520,778
| +165% | +$1.34M | ﹤0.01% | 3995 |
|
|
2024
Q2 | $710K | Buy |
315,664
+64,216
| +26% | +$129K | ﹤0.01% | 4630 |
|
|
2024
Q1 | $556K | Sell |
251,448
-7,241
| -3% | -$18.7K | ﹤0.01% | 4691 |
|
|
2023
Q4 | $608K | Buy |
258,689
+125,849
| +95% | +$232K | ﹤0.01% | 4650 |
|
|
2023
Q3 | $247K | Sell |
132,840
-91,302
| -41% | -$209K | ﹤0.01% | 4970 |
|
|
2023
Q2 | $587K | Buy |
224,142
+99,587
| +80% | +$254K | ﹤0.01% | 4653 |
|
|
2023
Q1 | $203K | Sell |
124,555
-39,285
| -24% | -$49.2K | ﹤0.01% | 5295 |
|
|
2022
Q4 | $218K | Buy |
163,840
+41,194
| +34% | +$58.1K | ﹤0.01% | 5270 |
|
|
2022
Q3 | $191K | Buy |
122,646
+10,106
| +9% | +$16.7K | ﹤0.01% | 5506 |
|
|
2022
Q2 | $173K | Sell |
112,540
-612,715
| -84% | -$1.29M | ﹤0.01% | 5692 |
|
|
2022
Q1 | $1.86M | Buy |
725,255
+497,564
| +219% | +$1.22M | ﹤0.01% | 4330 |
|
|
2021
Q4 | $667K | Buy |
227,691
+103,507
| +83% | +$224K | ﹤0.01% | 5168 |
|
|
2021
Q3 | $305K | Buy |
124,184
+26,190
| +27% | +$76K | ﹤0.01% | 5489 |
|
|
2021
Q2 | $399K | Buy |
97,994
+11,902
| +14% | +$45.4K | ﹤0.01% | 5348 |
|
|
2021
Q1 | $388K | Sell |
86,092
-132,152
| -61% | -$713K | ﹤0.01% | 5282 |
|
|
2020
Q4 | $1.07M | Buy |
218,244
+139,998
| +179% | +$700K | ﹤0.01% | 4155 |
|
|
2020
Q3 | $464K | Sell |
78,246
-82,286
| -51% | -$329K | ﹤0.01% | 4515 |
|
|
2020
Q2 | $427K | Buy |
160,532
+39,073
| +32% | +$136K | ﹤0.01% | 4453 |
|
|
2020
Q1 | $237K | Buy |
121,459
+102,759
| +550% | +$442K | ﹤0.01% | 4624 |
|
|
2019
Q4 | $132K | Sell |
18,700
-11,287
| -38% | -$93.2K | ﹤0.01% | 5006 |
|
|
2019
Q3 | $295K | Buy |
29,987
+12,774
| +74% | +$144K | ﹤0.01% | 4694 |
|
|
2019
Q2 | $197K | Sell |
17,213
-25,361
| -60% | -$266K | ﹤0.01% | 4801 |
|
|
2019
Q1 | $427K | Buy |
+42,574
| New | +$546K | ﹤0.01% | 4486 |
|
|
2018
Q3 | – | Sell |
-28,500
| Closed | -$541K | – | 5813 |
|
|
2018
Q2 | $541K | Buy |
+28,500
| New | +$554K | ﹤0.01% | 4460 |
|
Other funds holding XERS
VCM
RA
N
VPM
Goldman Sachs's XERS Position: Q1 2026 in Review
Goldman Sachs increased its Xeris Biopharma Holdings (XERS) stake by 2.9% in Q1 2026, buying an estimated $300K and bringing the position to 1,613,650 shares worth $9.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3128.
Goldman Sachs first reported a position in XERS in Q2 2018 and has held it in 30 quarters since. The position peaked at $15.3M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.
- Goldman Sachs held 1,613,650 shares of Xeris Biopharma Holdings worth $9.36M as of Q1 2026.
- Goldman Sachs bought 45,229 Xeris Biopharma Holdings shares in Q1 2026, an estimated $300K.
- Xeris Biopharma Holdings made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3128 holding.
- Goldman Sachs first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 30 quarters since.
- Goldman Sachs's Xeris Biopharma Holdings position peaked at $15.3M in Q1 2025.
- 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.